Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market Report 2026

Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market Overview

• Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing market size has reached to $2.89 billion in 2025 • Expected to grow to $4.11 billion in 2030 at a compound annual growth rate (CAGR) of 7.3% • Growth Driver: Rising Diabetes Prevalence Fuels Growth Of The Market Due To Increasing Obesity Rates And Demand For Hormone-Mimicking Therapies • Market Trend: Enhancing Speed And Quality In Peptide API Production With All-In-One Solutions • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market?

Peptide therapeutics contract active pharmaceutical ingredient manufacturing refers to the outsourced production of peptide-based active pharmaceutical ingredients by specialized third-party manufacturers under strict regulatory compliance. These manufacturers offer services such as custom synthesis, purification, and good manufacturing practice (GMP)-grade production to support clinical trials and commercial supply of peptide therapeutics. The main scale of operation types of peptide therapeutics contract active pharmaceutical ingredient (API) manufacturing are preclinical or clinical and commercial. Preclinical or clinical refers to the early stages of drug development, encompassing lab-based research and human trials to evaluate the safety and efficacy of peptide drugs. The different synthesis methods include non-chemical synthesis and chemical synthesis for varied enterprise types, including both large enterprises and small and medium enterprises.

What Is The Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market Growth Forecast?

The peptide therapeutics contract active pharmaceutical ingredient (api) manufacturing market size is expected to see strong growth in the next few years. It will grow to $4.11 billion in 2030 at a compound annual growth rate (CAGR) of 7.3%. The growth in the forecast period can be attributed to expansion of cmo capabilities for peptide api, rising investment in advanced peptide synthesis technologies, growth of personalized medicine and biologics, increasing outsourcing by small and mid-size pharma companies, adoption of digital manufacturing and ai-based process optimization. Major trends in the forecast period include rising demand for contract manufacturing of peptide apis, increased focus on gmp-grade production and compliance, growth in outsourced peptide synthesis for clinical trials, expansion of process optimization and tech transfer services, adoption of custom peptide synthesis for personalized therapeutics.

Global Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market Segmentation

1) By Scale Of Operation: Preclinical Or Clinical, Commercial 2) By Synthesis Method: Non Chemical Synthesis, Chemical Synthesis 3) By Enterprise Type: Large Enterprise, Small And Medium Enterprises Subsegments: 1) By Preclinical Or Clinical: Discovery And Preclinical Development, Phase II Or III Manufacturing, Phase I Manufacturing 2) By Commercial: Commercial-Scale Good Manufacturing Practice Manufacturing, Tech Transfer And Scale-up, Lifecycle Management Or Process Optimization

What Is The Driver Of The Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market?

The rising prevalence of diabetes is expected to propel the growth of the peptide therapeutics contract active pharmaceutical ingredient (API) manufacturing market going forward. Diabetes refers to a chronic metabolic disorder marked by elevated blood sugar (glucose) levels resulting from the body’s insufficient insulin production or its inability to use insulin effectively. The growing prevalence of diabetes is primarily fueled by increasing obesity rates, as excess body fat contributes to insulin resistance and disrupts blood sugar control. Peptide therapeutics leverage contract API manufacturing to enable large-scale production of hormone-mimicking drugs, enhancing insulin secretion and glucose control in diabetes management. For instance, in March 2025, according to the report published by the Office for Health Improvement and Disparities, a UK-based government department, the recorded prevalence of type 2 diabetes among adults aged 17 and over in England was 7.0% as of March 2024, up from 6.8% in March 2023. Therefore, the rising prevalence of diabetes is driving the growth of the peptide therapeutics contract active pharmaceutical ingredient (API) manufacturing industry.

Key Players In The Global Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market

Major companies operating in the peptide therapeutics contract active pharmaceutical ingredient (api) manufacturing market are Thermo Fisher Scientific Inc., Lonza Group AG., WuXi AppTec Co. Ltd., Cambrex Corporation, ChemPartner, GenScript Biotech Corporation, Bachem Group, CordenPharma International GmbH, Syngene International Limited, Ambiopharm Inc., CPC Scientific Inc., ScinoPharm Taiwan Ltd., Hybio Pharmaceutical Co. Ltd., CSBio Company Inc., Senn Chemicals AG., AnaSpec Inc., LifeTein LLC, Apex Biotechnology Corp., BCN Peptides S.A.

Global Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market Trends and Insights

Major companies operating in the peptide therapeutics contract active pharmaceutical ingredient (API) manufacturing market are focusing on developing innovative solutions, such as the continuous flow synthesis platform, to streamline production and address growing complexity in drug development. The continuous flow synthesis platform integrates multiple stages, reaction, separation, concentration, and crystallization, into a single, uninterrupted process with real-time in-line measurement, enabling high-precision, non-destructive monitoring and efficient scale-up. For instance, in May 2023, SynCrest Inc., a Japan-based contract research, development, and manufacturing organization (CRDMO), announced the launch of its good manufacturing practice (GMP)-compliant Naruto Plant equipped with a continuous flow synthesis platform for peptide and nucleotide API production. The platform enables the rapid and high-quality manufacturing of over 100 types of non-natural amino acids and high-purity special amidites, significantly reducing lead times and production costs. This innovation is addressing growing market demand for advanced peptide-based therapeutics by offering scalable, efficient, and cost-effective API manufacturing solutions.

What Are Latest Mergers And Acquisitions In The Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market?

In December 2024, Novo Holdings A/S, a Denmark-based asset management company, acquired Catalent Inc. for $16.5 billion. Through this acquisition, Novo Holdings A/S aims to optimize the development and delivery of life-changing therapies, improve global patient outcomes, and generate sustainable value in life sciences via its engaged ownership model. Catalent Inc. is a US-based pharmaceutical company that provides contract manufacturing services for active pharmaceutical ingredients (APIs), including peptide therapeutics APIs.

Regional Insights

North America was the largest region in the peptide therapeutics contract active pharmaceutical ingredient (API) manufacturing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market?

The peptide therapeutics contract active pharmaceutical ingredient (API) manufacturing market includes revenues earned by entities through custom peptide synthesis, process development and optimization, and analytical development and quality control. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Peptide Therapeutics Contract Active Pharmaceutical Ingredient (API) Manufacturing Market Report 2026?

The peptide therapeutics contract active pharmaceutical ingredient (api) manufacturing market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the peptide therapeutics contract active pharmaceutical ingredient (api) manufacturing industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.